Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.14 p
-0.02 p(-10.97%)
At close: 4:00 PM EDT
0.14 p
-0.02 p(-10.97%)
Day’s Range― - ―
52-Week Range0.12 p - 0.40 p
Previous CloseN/A
Volume29.11M
Average Volume (3M)34.43M
Market Cap
£8.30M
Enterprise Value12.65M
Total Cash (Recent Filing)£1.72M
Total Debt (Recent Filing)£75.00K
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces repayment pressure and lowers immediate financial risk. This gives Solvonis greater flexibility to fund operations or pursue development activities without the added constraints typically created by heavy borrowing.
Positive Equity BaseA positive and growing equity base provides a solvency cushion against continued operating losses. Although returns remain negative, this capital foundation may help the company sustain operations while it seeks to improve its business performance.
Cash Burn Tracks Reported LossesThe close alignment between cash burn and reported losses suggests there are no clear signs of a materially worse cash conversion problem beyond the underlying unprofitability. This improves transparency around funding needs, even though cash generation remains negative.
Bears Say
Persistent Operating LossesRecurring operating and net losses indicate that the business has not yet established a sustainable profit model. Without a clear path to positive earnings, continued losses can erode equity and increase reliance on future financing or strategic changes.
Revenue Near ZeroRevenue falling effectively to zero signals severe weakness in commercial activity and limits the company’s ability to absorb fixed costs. The lack of recent revenue scale also makes margin improvement and a durable operating model difficult to demonstrate.
Persistent Negative Free Cash FlowSustained negative operating cash flow and free cash flow indicate that Solvonis consumes cash rather than funding itself. Worsening cash needs increase the risk of dilution, asset sales, or other financing requirements if performance does not improve.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest share price was 0.12 p and its highest was 0.40 p in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is £8.30M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Sep 24, 2026 which is in 27 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Apr 29, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.781%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―